Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.

ABSTRACT:

Aim

To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil.

Patients and methods

Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.

Results

GEP stratified by TIS^HIGH vs. TIS^LOW demonstrated OS benefit (NR vs. 5.8 months HR 0.23; p = 0.0379), and in particular, MHC-II elevated baseline expression was correlated with OS advantage (p = 0.038). Moreover, 1-year OS was 75% in TIS^HIGH patients vs. 25% in TIS^LOW (p = 0.03795). OS was also correlated with positive γ-IFN ELISPOT response, 36.8 vs. 23.0 months (HR 0.19, p = 0.0098).

Conclusion

Vigil demonstrates OS benefit in correlat

SUBMITTER: Rocconi RP 

PROVIDER: S-EPMC8402348 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature